Enterprise Value
5.585B
Cash
348.3M
Avg Qtr Burn
N/A
Short % of Float
5.06%
Insider Ownership
0.99%
Institutional Own.
96.56%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TLANDO Details TRT (Testosterone Replacement Therapy) | Approved Update | |
DARZALEX (daratumumab) Details MM (Multiple myeloma) | Approved Quarterly sales | |
Hylenex (hyaluronidase human injection) Details Drug absorption | Approved Quarterly sales | |
Xyosted (testosterone enanthate) Details Testosterone replacement | Approved Quarterly sales | |
Otrexup (Methotrexate) Details RA (rheumatoid arthritis) and psoriasis | Approved Quarterly sales | |
DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Details AL (Light Chain) Amyloidosis | Approved Quarterly sales | |
Tecentriq® SC w/ ENHANZE Details Solid tumor/s, Cancer | PDUFA Approval decision | |
Selatogrel (P2Y12 receptor antagonist) Details Acute myocardial infarction | Phase 3 Data readout | |
OCREVUS® (ocrelizumab) w/ ENHANZE Details Multiple sclerosis | Phase 3 Update |